吉西他滨联合顺铂治疗晚期乳腺癌的临床观察

目的探讨吉西他滨联合顺铂方案治疗一线治疗后失败的晚期乳腺癌的临床疗效和不良反应。方法对入组的32例经病理证实的既往治疗后进展的乳腺癌患者,应用吉西他滨1000mg/m2,静滴,第1天、第8天;顺铂25mg/m2,静滴,第2～4天;联合化疗,每21天为1个周期。至少2个周期后评价疗效。结果 32例患者中,部分缓解(CR)3例(9.4%),完全缓解(PR)15例(46.9%),疾病稳定(SD)9例(28.1%),疾病进展(PD)5例(15.6%),总有效率(CR+PR)56.3%,临床获益率为84.4%。中位疾病进展时间(TTP)8.7个月。1年生存率62.5%。不良反应以骨髓抑制、消化道反应最为常见。结论应用吉西他滨联合顺铂治疗既往化疗后进展的晚期乳腺癌,疗效较好,不良反应较轻,值得临床推广应用。

Efficacy of combination chemotherapy with gemcitabine plus cisplatin in advanced breast cancer patients

Objective To observe the Clinical efficacy and toxicity of combination chemotherapy with gemcitabine plus cisplatin after the failure of first-line treatment in advanced breast cancer patients.Methods combination chemotherapy with gemcitabine(1000mg/m2 ivgtt d1.8) plus cisplatin(25mg/m2,ivgtt d2～4) in 32 advanced breast cancer patients confirmed by Pathology after the failure of first-line treatment.21 days for 1 cycle.At least 2 cycle therapeutic evaluation.Results In 32 cases,CR 3 cases(9.4%),PR 15 cases(46.9%),SD 9 cases(28.1%),PD 5 cases(15.6%),total effective rate(CR+PR)56.3%,Clinical benefit ratio 84.4%.mTTP 8.7months.1 year survival rate 62.5%.The most common adverse reaction are bone marrow suppression and gastrointestinal reaction.Conclusions Good clinical curative effect and light adverse reaction are achived in combination chemotherapy with gemcitabine plus cisplatin after the failure of first-line treatment in advanced breast cancer patients,and it worthy of clinical application.